MARKET

SKYE

SKYE

Skye Bioscience
NASDAQ
0.8800
+0.0173
+2.01%
Pre Market: 0.8166 -0.0634 -7.20% 05:18 05/12 EDT
OPEN
0.8800
PREV CLOSE
0.8627
HIGH
0.9049
LOW
0.8383
VOLUME
157
TURNOVER
0
52 WEEK HIGH
5.75
52 WEEK LOW
0.5655
MARKET CAP
30.91M
P/E (TTM)
-0.6241
1D
5D
1M
3M
1Y
5Y
1D
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
Reuters · 3h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)
TipRanks · 4h ago
SKYE BIOSCIENCE INC <SKYE.O>: PIPER SANDLER CUTS TARGET PRICE TO $6 FROM $13
Reuters · 8h ago
Skye Bioscience reports Q1 EPS (32c), consensus (32c)
TipRanks · 13h ago
Skye Bioscience Q1 EPS $(0.32) Misses $(0.31) Estimate
Benzinga · 14h ago
Skye Bioscience GAAP EPS of -$0.32
Seeking Alpha · 14h ago
*Skye Bioscience 1Q Loss/Shr 32c >SKYE
Dow Jones · 14h ago
Skye Bioscience Q1 FY26 net loss widens to $12.51 million; operating loss rises to $12.67 million
PUBT · 14h ago
More
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Webull offers Skye Bioscience Inc stock information, including NASDAQ: SKYE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SKYE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SKYE stock methods without spending real money on the virtual paper trading platform.